News & Updates

Age does not affect palbociclib dose reduction, discontinuation in breast cancer patients
Age does not affect palbociclib dose reduction, discontinuation in breast cancer patients
06 Jan 2023

The age of patients with advanced breast cancer appears to have no influence on the rate of palbociclib dose reductions or discontinuations secondary to neutropaenia, a study has shown.

Age does not affect palbociclib dose reduction, discontinuation in breast cancer patients
06 Jan 2023
Can breast cancer survivors temporarily stop endocrine therapy to attempt pregnancy?
Can breast cancer survivors temporarily stop endocrine therapy to attempt pregnancy?
05 Jan 2023 byRoshini Claire Anthony

Young breast cancer survivors could safely temporarily stop adjuvant endocrine therapy (ET) to attempt pregnancy, according to primary results of the POSITIVE* trial presented at SABCS 2022.

Can breast cancer survivors temporarily stop endocrine therapy to attempt pregnancy?
05 Jan 2023
5α-reductase inhibitor treatment implicated in dementia
5α-reductase inhibitor treatment implicated in dementia
05 Jan 2023

Men who are receiving treatment with 5α-reductase inhibitors (5-ARIs) are at increased risk of dementia in the immediate period after initiating treatment, a study has shown. Of note, both finasteride and dutasteride are associated with depression, but neither of them is linked to suicide.

5α-reductase inhibitor treatment implicated in dementia
05 Jan 2023
Postoperative neutropaenia tied to early CRBSI in children with leukaemia
Postoperative neutropaenia tied to early CRBSI in children with leukaemia
05 Jan 2023 byStephen Padilla

Paediatric patients with acute myeloid leukaemia and other leukaemias (AML/OLs), especially those with persistent neutropaenia during the first 30 postoperative days, are at increased risk of early catheter-related bloodstream infections (CRBSIs), according to a Singapore study.

Postoperative neutropaenia tied to early CRBSI in children with leukaemia
05 Jan 2023